{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:34:41Z","timestamp":1794980081522,"version":"4.9.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.atherosclerosis.2025.120495","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:44:16Z","timestamp":1755845056000},"page":"120495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Understanding MASLD \u2014 from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist"],"prefix":"10.1016","volume":"409","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1065-2972","authenticated-orcid":false,"given":"Carlo","family":"Ratti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Malaguti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D'Aniello","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120495_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117523","article-title":"Metabolic dysfunction-associated steatotic liver disease: an opportunity for collaboration between cardiology and hepatology","volume":"392","author":"Raggi","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib2","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","article-title":"Trends in the prevalence of metabolic dysfunction\u2013associated fatty liver disease in the United States, 2011\u20132018","volume":"20","author":"Wong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1152\/physiol.00013.2023","article-title":"NAFLD: an emerging causal factor for cardiovascular disease","volume":"38","author":"Li","year":"2023","journal-title":"Physiology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib8","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221139101","article-title":"MAFLD: what 2 years of the redefinition of fatty liver disease has taught Us","volume":"13","author":"Grabherr","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib12","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.jhep.2023.09.038","article-title":"From NAFLD to MASLD: promise and pitfalls of a new definition","volume":"81","author":"Cusi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-10380-9","article-title":"Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study","volume":"15","author":"Jeong","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119161","article-title":"Liver and atherosclerotic risk of alcohol consumption in patients with metabolic dysfunction-associated steatotic liver disease","volume":"403","author":"Wang","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up","volume":"81","author":"Kwak","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512175","article-title":"Phosphatidylethanol (PEth) in blood as a marker of unhealthy alcohol use: a systematic review with novel molecular insights","volume":"24","author":"Perilli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib19","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications","volume":"16","author":"Tana","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12876-017-0592-y","article-title":"Non alcoholic fatty liver disease and eNOS dysfunction in humans","volume":"17","author":"Persico","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00125-011-2444-6","article-title":"Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes","volume":"55","author":"St\u00e5hlman","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non\u2010alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib25","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib26","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib27","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/cells11162511","article-title":"Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review","volume":"11","author":"Nasiri-Ansari","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2337\/db08-0775","article-title":"Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis Factor-\u03b1 expression","volume":"58","author":"Yuen","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3350\/cmh.2024.0315","article-title":"Immunological mechanisms in steatotic liver diseases: an overview and clinical perspectives","volume":"30","author":"Yan","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative stress in non-alcoholic fatty liver disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Livers"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib32","article-title":"Reactive oxygen species induce fatty liver and ischemia-reperfusion injury by promoting inflammation and cell death","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib33","first-page":"377","article-title":"Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease","volume":"3","author":"Bieghs","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB\u20104, NAFLD fibrosis score and APRI for NAFLD\u2010related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib40","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.cgh.2023.04.026","article-title":"Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population","volume":"21","author":"Seo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib41","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib42","article-title":"A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions","volume":"15","author":"Mendez","year":"2022","journal-title":"Int J Cardiol Cardiovascular Risk and Prevention"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib43","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications","volume":"16","author":"Tana","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101511","article-title":"Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis","volume":"29","author":"Vega","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","article-title":"Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study","volume":"22","author":"Simon","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib48","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"2023","key":"10.1016\/j.atherosclerosis.2025.120495_bib49","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction\u2010associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the heart failure association of the european society of cardiology, heart failure society of America and Japanese heart failure society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s11357-024-01435-2","article-title":"Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults","volume":"47","author":"Clayton-Chubb","year":"2025","journal-title":"Geroscience"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16218","article-title":"MASLD is associated with an increased long-term risk of atrial fibrillation: an updated systematic review and meta-analysis","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101171","article-title":"Inflammation in liver fibrosis and atrial fibrillation: a prospective population-based proteomic study","volume":"6","author":"Boeckmans","year":"2024","journal-title":"JHEP Reports"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib55","doi-asserted-by":"crossref","DOI":"10.4330\/wjc.v17.i6.106147","article-title":"Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: a review of pathogenesis","volume":"17","author":"Bharaj","year":"2025","journal-title":"World J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1573841","article-title":"Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: molecular and clinical aspects","volume":"12","author":"Cheung","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut\u2013liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib59","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib61","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/nu10121971","article-title":"Trimethylamine-N-oxide (TMAO) as novel potential biomarker of early predictors of metabolic syndrome","volume":"10","author":"Barrea","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0954422420000177","article-title":"Trimethylamine N -oxide: heart of the microbiota\u2013CVD nexus?","volume":"34","author":"Naghipour","year":"2021","journal-title":"Nutr Res Rev"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib63","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2019.11.006","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.03289","article-title":"Comparative evaluation of microbiota engraftment following fecal microbiota transfer in mice models: age, kinetic and microbial status matter","volume":"9","author":"Le Roy","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib65","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","article-title":"Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases","volume":"39","author":"Loguercio","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib66","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib67","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly Obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS\u2010CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib71","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (<scp>GIP<\/scp> and <scp>GLP<\/scp> \u20101) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib74","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib75","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib76","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib77","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long\u2010term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5\u2010year follow\u2010up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib78","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.14670","article-title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","volume":"24","author":"Kahl","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib79","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib80","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non\u2010alcoholic fatty liver disease (<scp>NAFLD<\/scp>) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib81","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib82","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and safety of apararenone (MT\u20103995) in patients with nonalcoholic steatohepatitis: a randomized controlled study","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.atherosclerosis.2025.120495_bib84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T11:03:58Z","timestamp":1763204638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025013930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":84,"alternative-id":["S0021915025013930"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120495","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding MASLD \u2014 from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120495"}}